Physician profile
Tara Sarin
NPI 1760860134
$20,135.69
in general payments reported to CMS, 2019-2025
34 companies · $3,367 in 2025
The $3,367 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $588 · 2021: $2,827 · 2022: $3,719 · 2023: $6,153 · 2024: $2,417 · 2025: $3,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,787 · Consulting Fee: $3,836 · Honoraria: $175 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,786.77 |
| Consulting Fee | $3,836.25 |
| Honoraria | $175.00 |
| Education | $139.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,470.31 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $4,172.73 | 2019-2025 | |
| Genentech USA, INC. | $2,217.39 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $1,126.27 | 2020-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $666.99 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $665.36 | 2020-2025 | Eohilia, Cuvitru, Hyqvia |
| Glaxosmithkline, LLC. | $586.18 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $417.91 | 2022-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $373.20 | 2020-2025 | Dupixent |
| Kaleo, INC. | $362.14 | 2020-2024 | Auvi-Q |
| Grifols USA, LLC | $275.15 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Aimmune Therapeutics, INC. | $267.96 | 2020-2024 | |
| Csl Behring | $245.78 | 2021-2025 | Hizentra, Haegarda |
| Optinose US, INC. | $225.67 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $203.90 | 2020-2023 | Airduo Digihaler |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $191.27 | 2021-2025 | |
| Regeneron Pharmaceuticals, INC. | $182.60 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $180.04 | 2023-2025 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $170.49 | 2025 | Neffy |
| Incyte Corporation | $138.33 | 2025 | Opzelura |
| Abbvie INC. | $118.60 | 2023 | Rinvoq |
| Blueprint Medicines Corporation | $100.64 | 2024-2025 | Ayvakit |
| Genentech, INC. | $88.61 | 2024 | Xolair |
| Biocryst US Sales Co., LLC | $88.00 | 2022-2023 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.63 | 2020-2023 | Spiriva Respimat |
| Ionis Pharmaceuticals, INC. | $55.96 | 2025 | Dawnzera |
| Mylan Specialty L.P. | $55.00 | 2023-2024 | Yupelri |
| Galderma Laboratories, L.P. | $52.06 | 2025 | Nemluvio |
| Greer Laboratories, INC. | $24.49 | 2025 | Oralair |
| Lilly USA, LLC | $24.37 | 2025 | Ebglyss |
| Organon LLC | $21.29 | 2025 | |
| Octapharma USA, INC. | $20.45 | 2022 | |
| Tersera Therapeutics LLC | $18.65 | 2025 | Quzyttir |
| Paratek Pharmaceuticals, INC. | $18.45 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Sarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.